期刊文献+

血管内皮生长因子C与胰腺癌根治术后复发的相关性研究 被引量:5

The relationship between vascular endothelial growth factor C and recurrence following curative resectionof pancreatic cancer
原文传递
导出
摘要 目的探讨血管内皮生长因子C(VEGF-C)表达及多种临床病理因素在预测胰腺癌根治术后复发的价值。方法应用Envision免疫组化法测定47例胰腺癌根治性切除标本中胰腺癌组织和自身胰腺正常组织中VEGF-C的表达。通过Kaplan-Meier生存分析和Cox风险比例模型,评估VEGF-C和各临床病理因素对胰腺癌根治术后复发的影响。结果VEGF—C在胰腺癌组织中的表达比例及其在自身正常胰腺组织中的表达比例分别为29例(61.7%)、7例(14.9%),VEGF-C在胰腺癌组织中的表达比例明显高于其在自身正常胰腺组织中的表达(P=0.018)。胰腺癌根治术后患者无病中位生存期为11.9个月,平均为(18.4±2.4)个月。1年、2年、3年累计无病生存率分别为46.8%、23.4%和14.4%。VEGFC的表达与淋巴结转移有显著的相关性(P=0.036)。单因素生存分析显示VEGF=C(P=0.020)、肿瘤直径(P=0.013)、年龄(P=0.057)、术后辅助化疗(P=0.017)与无病生存期明显相关。Cox回归多因素分析显示,VEGF-C(P=0.009)、肿瘤直径(P=0.010)、术后辅助化疗(p=0.017)是胰腺癌根治术后患者无病生存期独立的预后因素。结论VEGFC在胰腺癌组织中表达明显增高,VEGF—C的表达与淋巴结转移有显著的相关性,VEGF—C可作为判断胰腺癌根治术后患者无病生存期的独立指标。 Objective To investigate the prognostic value of vascular endothelial growth factor C (VEGF C) and clinicopathologic indexes in predicting recurrence following curative resection of pancreatic cancer. Methods The expressions of VEGFC of 47 patients who underwent curative resection for curative pancreatic cancer resection were detected by Envision immunohistochemical methods. The effects of VEGF-C and clinicopathologic indexes on recurrence were assessed by the Kaplan-Meier and Cox proportional hazards model. Results The positive rates of VEGF C were 61.7%(n = 29) and 14.9%(n =7), respectively, in pancreatic cancer and normal pancreatic tissues. The positive expres sion of VEGF-C in pancreatic carcinoma was obviously higher than the normal pancreatic tissues (P=0. 018). The median disease-free survival time was 11.9 months, the average disease-free survival time was 18.4±2. 4 months, and the cumulative 1 year, 2-year and 3-year actuarial recurrence free survival rates were 46. 8%, 23. 4%, 14. 4%, respectively. There was a significant correlation between the VEGF-C expression and lymph node metastasis in pancreatic cancer (P=0. 036). On Kaplan-Meier analysis, VEGF-C (P=0. 020), tumor diameter (P=0. 013), age (P=0. 057) and adjuvant chemotherapy (P=0. 017) were associated with disease-free survival time. Multivariate analysis showed VEGF-C (P=0. 009), tumor diameter (P=0. 010) and adjuvant chemotherapy (P=0. 017) were independent prognostic factors of disease-free survival after surgery for pancreatic cancer. Conclusion The expression of VEGF-C was higher in pancreatic cancer, and VEGF-C was correlated with lymph node metastasis. VEGF-C was the biomarker that independently predicted disease-free survival after surgery for pancreatic cancer.
出处 《中华肝胆外科杂志》 CAS CSCD 北大核心 2011年第6期479-483,共5页 Chinese Journal of Hepatobiliary Surgery
基金 国家自然科学基金资助(30400438)
关键词 胰腺肿瘤 胰腺切除术 复发 血管内皮生长因子C 多因素分析 Pancreatic neoplasm Curative resection Recurrence Vascular endothelial growth factor C Multivariate analysis
  • 相关文献

参考文献15

  • 1Matsuno S, Egawa S, Fukuyama S, et al. Pancreatic cancer registry in Japan: 20 years of experience. Pancreas, 2004, 28:219-230.
  • 2Cameron JL, Riall TS, Coleman J, et al. One thousand con- secutive pancreaticoduodenectomies. Ann Surg, 2006, 244: 10-15.
  • 3Joukov V, Kalkkinen N, Alitalo K, et al. A novel vascularen- dothelial growthfactor, VEGF C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J, 1996, 15:290 -298.
  • 4Nisato RE, Tille JC, Pepper MS. Lymphangiogenesis and tumor metastasis. Thromb Haemost, 2003,90 :591-597.
  • 5Schietroma C, Cianfarani F, Lacal PM, et al. Vascular endo- thelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer, 2003, 98:789-797.
  • 6Hung CJ, Ginzinger DG, Zarnegar R, et al. Expression of vascular endothelial growth factor C in benign and malignant thyroid tumors. J Clin Endocrinol Metab, 2003, 88: 3694- 3699.
  • 7Mylona E, Alexandrou P, Mpakali A, et al. Clinicopathologi- cal and prognostic significance of vascular endothelial growth factors (VEGF)-C and-D and VEGF receptor 3 in invasive breast carcinoma. Eur J Surg Oncol, 2007,33 : 294-300.
  • 8Arigami T, Natsugoe S, Uenosono Y, et al. Vascular endo- thelial growth factor-C and-D expression correlates with lymph node micrometastasis in pN0 early gastric cancer. J Surg On- col, 2009,99:148 -153.
  • 9Kawakami M, Furuhata T, Kimura Y, et al. Quantification of vascular endothelial growth factor-C and its receptor-3 mes- senger RNA with real time quantitative polymerase chain reac- tion as a predictor of lymph node metastasis in human coloree tal cancer. Surgery, 2003,133 : 300-308.
  • 10Tang RF,Itakura J, Aikawa T, et al. Overexpression of lym- phangiogenic growth factor VEGF C in human pancreatic cancer. Pancreas, 2001,22 : 285 -292.

二级参考文献8

  • 1Jemal A, Siegel R, Ward E, et al. Cancer Statistics 2008. CA Cancer J Clin, 2008,58:71-96.
  • 2Lochan R, Daly AK, Reeves HL, et al, Genetic susceptibility in pancreatic ductal adenoearcinoma. Bri J Surg, 2008,95 : 22-32.
  • 3Hassan MM, Bondy ML, Wolff RA, et al. Risk Factors for Pancreatic Cancer: Case-Control Study. Am J Gastroenterol, 2007, 102: 2696-2707.
  • 4Katz MH, Hwang R, Fleming JB, et al. Tumor-node-metastasis staging of pancreatic adenocarcinoma. CA Cancer J Clin, 2008,58:111-125.
  • 5Raut CP, Tseng JF, Sun CC, et al. Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma. Ann Surg, 2007,246 : 52- 60.
  • 6Westgaard A, Tafjord S, Farstad IN, et al, Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer, 2008,14:5.
  • 7Samra JS, Gananadha S, Hugh TJ. Surgical management of carcinoma of the head of pancreas: extended iymphadenectomy of modified en bloc resection? ANZ J Surg, 2008, 78:228-236.
  • 8Farnell MB, Aranha GV, Nimura Y, et al. The role of extended lymphadenectomy for adenocareinoma of the head ofthe pancreas: strength of the evidence. J Gastrointest Surg, 2008, 12:651-656.

共引文献43

同被引文献50

  • 1María Martell,Mar Coll,Nahia Ezkurdia,Imma Raurell,Joan Genescà.Physiopathology of splanchnic vasodilation in portal hypertension[J].World Journal of Hepatology,2010,2(6):208-220. 被引量:14
  • 2Hui Cao,Jia Xu,Rong Hua,Fang-Bin Meng,Jiang-Feng Qiu,Zhi-Yong Wu.Expression of cyclooxygenase in hyperdynamic portal hypertensive rats[J].Hepatobiliary & Pancreatic Diseases International,2006,5(2):252-256.
  • 3张丽萍,聂青,康静波,李建国,齐文杰.伽玛刀治疗晚期胰腺癌的临床研究[J].中国现代医学杂志,2005,15(5):723-725. 被引量:12
  • 4陆以霞,任旭,张玲玲.CEA、CA19-9、CA50水平与胰腺癌分期和肿瘤大小的关系[J].胰腺病学,2006,6(5):266-268. 被引量:9
  • 5张太平,赵玉沛.胰腺癌基因治疗的现状与展望[J].中华肝胆外科杂志,2007,13(3):148-151. 被引量:7
  • 6Mielgo A, Schmid MC. Impact of tumour associated macrophages in pancreatic cancer[ J]. BMB Rep,2013,46(3 ) : 131-138.
  • 7Partecke LI, Gtinther C, Hagemann S, et al. Induction of M2-mac- rophages by tumour cells and tumour growth promotion by M2-mac- rophages: a quid pro quo in pancreatic cancer[ J]. Pancreatology, 2013,13(5) :508-516.
  • 8Yoshikawa K, Mitsunaga S, Kinoshita T, et al. Impact of tumor-as- sociated macrophages on invasive ductal carcinoma of the pancreas head[ J]. Cancer Sci ,2012,103 ( 11 ) :2012-2020.
  • 9Sideras K, Braat H, Kwekkeboom J, et al. Review : Role of the im- mune system in pancreatic cancer progression and immune modula- ting treatment strategies [ J ]. Cancer Treat Rev, 2014,40 ( 4 ) : 513-522.
  • 10Mitchem JB, Brennan D J, Knolhoff BL, et al. Targeting tumor-in- filtrating macrophages decreases tumor-initiating cells, relieves im- munosuppression, and improves chemotherapeutic responses [ J ]. Cancer Res,2013,73(3) :1128-1141.

引证文献5

二级引证文献32

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部